New radiopharmaceutical to be trialed as prostate cancer therapy
The radiopharmaceutical, I-131-MIP-1466, which is designed to deliver a therapeutic dose of radiation to metastatic prostate cancer, will enter a clinical trial to evaluate its efficacy and benefits for patients.
The radiopharmaceutical will be manufactured by the Centre for Probe Development and Commercialization (CPDC) in Hamilton, Ontario, for the developer of the compound, Molecular Insight Pharmaceuticals, based in Cambridge, Mass.
The trial, anticipated to start in early 2013, will mark the first time that a small-molecule-based radiopharmaceutical targeting prostate-specific membrane antigen, a type of protein expressed in high levels on prostate tumors, will be tested for its ability to treat prostate tumors that have spread throughout the body, according to CPDC.
The radiopharmaceutical will be manufactured by the Centre for Probe Development and Commercialization (CPDC) in Hamilton, Ontario, for the developer of the compound, Molecular Insight Pharmaceuticals, based in Cambridge, Mass.
The trial, anticipated to start in early 2013, will mark the first time that a small-molecule-based radiopharmaceutical targeting prostate-specific membrane antigen, a type of protein expressed in high levels on prostate tumors, will be tested for its ability to treat prostate tumors that have spread throughout the body, according to CPDC.